Education
About Us
Working with TipRanks
Follow Us
Hims & Hers Health (HIMS)
NYSE:HIMS
HIMS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$11.20 - $72.98
Previous CloseN/A
Volume4.28M
Average Volume (3M)22.21M
Market Cap
$5.74B
Enterprise Value$5.53B
Total Cash (Recent Filing)$220.58M
Total Debt (Recent Filing)$11.35M
Price to Earnings (P/E)48.3
Beta2.75
Next Earnings
May 05, 2025EPS Estimate
0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.53
Shares Outstanding213,787,950
10 Day Avg. Volume20,262,527
30 Day Avg. Volume22,209,099
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)5.23
Price to Cash Flow (P/CF)22.30
P/FCF Ratio22.30
Enterprise Value/Market Cap0.96
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit4.72
Enterprise Value/Ebitda75.85
Forecast
1Y Price Target
$45.77Price Target Upside80.55% Upside
Rating ConsensusHold
Number of Analyst Covering13
---
Bulls Say, Bears Say
Bulls Say
Brand Recognition And Product DiversityHIMS is relatively better positioned than private peers to retain current customers given brand recognition and diversity of SKUs.
Historical Guidance IncreasesHIMS has historically raised guidance every quarter going back to 4Q’21.
Bears Say
Decline In Sales GrowthObserved sales growth y/y decelerated 45ppts to 78% in March, reversing a five-month streak of accelerating growth.
FDA Alert On FinasterideThe U.S. Food & Drug Administration (FDA) issued an alert on the potential risks associated with compounded topical finasteride products.
Marketing And Advertising PullbackSignificantly fewer HIMS GLP-1 ads are noticed throughout social media feeds and less on TV, indicating a pullback in GLP-1 marketing spend.
---
Ownership Overview
10.27% Insiders
16.26% Mutual Funds
0.19% Other Institutional Investors
53.08% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
The estimated number of people who visited one or more of the websites owned by Hims & Hers Health
Desktop Users
Mobile Users
HIMS FAQ
What was Hims & Hers Health’s price range in the past 12 months?
Hims & Hers Health lowest stock price was $11.20 and its highest was $72.98 in the past 12 months.
What is Hims & Hers Health’s market cap?
Hims & Hers Health’s market cap is $5.74B.
When is Hims & Hers Health’s upcoming earnings report date?
Hims & Hers Health’s upcoming earnings report date is May 05, 2025 which is in 11 days.
How were Hims & Hers Health’s earnings last quarter?
Hims & Hers Health released its earnings results on Feb 24, 2025. The company reported $0.11 earnings per share for the quarter, beating the consensus estimate of $0.108 by $0.002.
Is Hims & Hers Health overvalued?
According to Wall Street analysts Hims & Hers Health’s price is currently Undervalued.
Does Hims & Hers Health pay dividends?
Hims & Hers Health does not currently pay dividends.
What is Hims & Hers Health’s EPS estimate?
Hims & Hers Health’s EPS estimate is 0.12.
How many shares outstanding does Hims & Hers Health have?
Hims & Hers Health has 213,787,950 shares outstanding.
What happened to Hims & Hers Health’s price movement after its last earnings report?
Hims & Hers Health reported an EPS of $0.11 in its last earnings report, beating expectations of $0.108. Following the earnings report the stock price went down -22.315%.
Which hedge fund is a major shareholder of Hims & Hers Health?
Currently, no hedge funds are holding shares in HIMS
---
Hims & Hers Health Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$45.77 (80.55% Upside)
$45.77 (80.55% Upside)
Blogger Sentiment
Bullish
HIMS Sentiment 80%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 7.9M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $3.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days <0.1%
Last 30 Days ▲ 4.4%
Last 30 Days ▲ 4.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
113.38%
12-Months-Change
Fundamentals
Return on Equity
30.71%
Trailing 12-Months
Asset Growth
64.29%
Trailing 12-Months
Company Description
Hims & Hers Health
Hims & Hers Health, Inc. operates a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals. The company offers a range of health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug and device products, cosmetics, and supplement products, primarily focusing on wellness, sexual health and wellness, skincare, and hair care. The company's curated non-prescription products include vitamin C, melatonin, biotin, and collagen protein supplements in the wellness category; moisturizer, serums, and face wash in the skincare category; condoms, climax delay spray and wipes, vibrators, and lubricants in the sexual health and wellness category; and shampoos, conditioners, scalp scrubs, and topical treatments, such as minoxidil in the hair care category. In addition, it offers medical consultation services, as well as health and wellness products through wholesale partners. The company is based in San Francisco, California.
---
HIMS Company Deck
---
HIMS Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted strong revenue and subscriber growth, along with strategic acquisitions and innovations in personalized treatment offerings. However, challenges such as declining gross margins, potential regulatory issues, and transitions in product offerings present notable risks. Overall, the positives in growth and strategic direction are tempered by these operational and regulatory concerns.Read More>---
HIMS Revenue Breakdown
96.60% Online
3.40% Wholesale
---
HIMS Stock 12 Month Forecast
Average Price Target
$45.77
▲(80.55% Upside)
Technical Analysis
Best Analysts Covering HIMS
1 Year
1 Year Success Rate
16/17 ratings generated profit
1 Year Average Return
+42.84%
reiterated a sell rating 3 days ago
Copying Allen Lutz's trades and holding each position for 1 Year would result in 94.12% of your transactions generating a profit, with an average return of +42.84% per trade.
---